Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

Roche

Status: Completed

Conditions: HCV

Study type: Observational

Funder types: Industry

Identifiers

NCT02452814

NP29710

Details and patient eligibility

About

Long Term Observational Extension Study Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination with Telaprevir and Ribavirin in Subjects with Chronic Hepatitis C Virus Genotype 1 Infection

Enrollment: 8 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participated in Study SPC3649-205 (this would include those who completed study SPC3649-205, those who discontinued or terminated the study early for whatever reason (including treatment failure) and those who opted to receive approved therapy for the treatment of HCV infection).

Exclusion criteria

• Those unwilling to provide informed consent for participation in this study.
• Subjects who have received investigational drug therapy after discontinuation, termination, or successful completion of Study SPC3649-205.

Trial design

8 participants in 1 patient group

Cohort